GLP-1 Advisor | One Day MD

GLP-1 & Obesity Medicine Guide • Updated October 2026 Semaglutide, tirzepatide and orforglipron represent three important stages in the evolution of incretin-based medicine: an established injectable GLP-1 receptor agonist, a dual GIP/GLP-1 agonist with greater average weight loss, and a next-generation oral GLP-1 receptor agonist designed to deliver GLP-1 therapy without an injection. But the phrase “best GLP-1 drug” can be misleading. These medicines do not have identical mechanisms, routes of administration, dose scales, indications or clinical-outcome evidence. And the headline weight-loss percentages come from different trials, so they cannot simply be placed in one league table as though the three drugs were tested against each other in a single randomized trial. The current evidence nevertheless gives us a useful framework. Tirzepatide currently has the strongest direct evidence for greater weight loss than semaglutide. Semaglutide remains a benchmark therapy w...

By the OneDayMD Editorial Team | Last updated: October 9, 2026 | Nutrition, Healthy Aging and Supplement Evidence From blueberries, leafy greens and fatty fish to creatine, magnesium and omega-3 supplements, nutrition advice can be surprisingly confusing. Some recommendations are supported by substantial research. Others rely on preliminary studies, biological theories or marketing claims that make the benefits sound more certain than they are. This guide brings together two important questions: Which nutrient-dense foods deserve a regular place on your plate, and which supplements are actually worth considering? The answer starts with a simple principle: build a healthy dietary pattern first, then use supplements to address a specific nutritional gap, medical indication or evidence-supported goal. No single food or supplement can replace a balanced diet, appropriate medical care, physical activity or sleep. Key takeaway: Prioritize minimally processed foods, vegetables...